PRINCE PAUL: Open Payments
NPI 1073746012 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$813 in 17 payments from 9 companies in 2025. Trend: 2023 $53 · 2024 $559 · 2025 $813
Food & beverage: $638Education: $175
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 5 | $273 |
| JAZZ PHARMACEUTICALS INC. | 2 | $167 |
| SANOFI-AVENTIS U.S. LLC | 1 | $102 |
| Janssen Biotech, Inc. | 3 | $96 |
| Merck Sharp & Dohme LLC | 2 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| SOBI, INC | 1 | $29 |
| Gamida Cell Inc. | 1 | $24 |
| Incyte Corporation | 1 | $20 |
Products named: RYLAZE, REZUROCK, DARZALEX, PREVYMIS, Cresemba, DEFITELIO, LIVTENCITY, Xospata.
Industry payments across TX — which companies pay providers there.
